This is a working overview of Dual agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-24 and is reviewed periodically as new material appears.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
The cooling trend since the mid-Holocene thermal maximum is consistent with ice core and pollen records, but the corresponding magnitude of cooling is elusive due to complicated influences from local effects such as humidity and soil water composition. The meaning of isotopes in cellulose and its applications is still an area of active study.
On May 13, the plane from Moscow landed in Madrid carrying on board the president of the PCE Dolores Ibárruri, the Pasionaria, who returned to Spain after a 38-year exile. The following day another exiled, Don Juan de Borbón, ceded his rights to the Spanish Crown to his son, King Juan Carlos I. By the end May, Torcuato Fernández Miranda, "an important architect of the transition as president of the Cortes", presented his resignation from his post, which "seemed to indicate the beginning of a new political stage".
==== Neurodegeneration ==== Research has been conducted on the effects of stem cells on animal models of brain degeneration, such as in Parkinson's disease, Amyotrophic lateral sclerosis, and Alzheimer's disease. Preliminary studies related to multiple sclerosis have been conducted, and a 2020 phase 2 trial found significantly improved outcomes for mesenchymal stem cell treated patients compared to those receiving a sham treatment. In January 2021 the FDA approved the first clinical trial for an investigational stem cell therapy to restore lost brain cells in people with advanced Parkinson's disease. Healthy adult brains contain neural stem cells, which divide to maintain general stem-cell numbers, or become progenitor cells. In healthy adult laboratory animals, progenitor cells migrate within the brain and function primarily to maintain neuron populations for olfaction (the sense of smell). Pharmacological activation of endogenous neural stem cells has been reported to induce neuroprotection and behavioral recovery in adult rat models of neurological disorders.
Once a food source is suspected, traceback investigations trace it through the supply chain to pinpoint where contamination occurred. Findings are reported to the CDC's National Outbreak Reporting System (NORS). In the United States, PulseNet, a national laboratory network established in 1996, uses whole genome sequencing (WGS) of bacterial isolates to link cases across jurisdictions that might otherwise appear unrelated. Prior to WGS, pulsed-field gel electrophoresis (PFGE) served as the standard subtyping method for over two decades before being phased out in favor of the higher resolution offered by WGS.
Sources: en.wikipedia.org
The occurrence of diabetes in monozygotic and dizygotic twins has been tested, and these rates can give insight into the genetic component of diabetes. In type 1 diabetes, the chance of monozygotic twins both developing the disease was greater than the risk for dizygotic twins. However, the rate of any siblings contracting the disease was much greater with type 2 diabetes. This indicates that there must be a large environmental factor involved in type 2, and some genetic factor with type 1. Type 1 diabetes has only about a 50% concordance rate (the percentage of two identical twins both having the condition). Thus, it is not fully genetic, but the results from the twin studies point to some inherited risk. Type 1 diabetes can occur at any age, and a significant proportion is diagnosed during adulthood. Latent autoimmune diabetes of adults (LADA) is the diagnostic term applied when type 1 diabetes develops in adults; it has a slower onset than the same condition in children. Given this difference, some use the unofficial term "type 1.5 diabetes" for this condition. Adults with LADA are frequently initially misdiagnosed as having type 2 diabetes, based on age rather than a cause. LADA leaves adults with higher levels of insulin production than type 1 diabetes, but not enough insulin production for healthy blood sugar levels.
I have been frequently asked why I invented the name "Penicillin". I simply followed perfectly orthodox lines and coined a word which explained that the substance penicillin was derived from a plant of the genus Penicillium just as many years ago the word "Digitalin" was invented for a substance derived from the plant Digitalis.
=== Measuring the rate of nucleation === As of 2014, the classical nucleation theory explained that the nucleation rate will correspond to the driving force. One method for measuring the nucleation rate is through the induction time method. This process uses the stochastic nature of nucleation and determines the rate of nucleation by analysis of the time between constant supersaturation and when crystals are first detected. Another method includes the probability distribution model, analogous to the methods used to study supercooled liquids, where the probability of finding at least one nucleus at a given time is derived. As of 2019, the early stages of nucleation and the rates associated with nucleation were modelled through multiscale computational modeling. This included exploration into an improved kinetic rate equation model and density function studies using the phase-field crystal model.
The pH of an electrophoretic gel is determined by the buffer used for that gel. If the pH of the buffer is above the pI of the protein being run, the protein will migrate to the positive pole (negative charge is attracted to a positive pole). If the pH of the buffer is below the pI of the protein being run, the protein will migrate to the negative pole of the gel (positive charge is attracted to the negative pole). If the protein is run with a buffer pH that is equal to the pI, it will not migrate at all. This is also true for individual amino acids.
The males of ancient Greece believed that small penises were ideal. Scholars believe that most ancient Greeks probably had the same size penises as other Europeans, but Greek artistic portrayals of handsome youths show them with inordinately small, uncircumcised penises with disproportionately large foreskins, indicating that these were seen as ideal. Large penises in Greek art are reserved for comically grotesque figures, such as satyrs, a class of hideous, horse-like woodland spirits, who are shown in Greek art with absurdly massive penises. Actors portraying male characters in ancient Greek comedy wore enormous, fake, red penises, which dangled underneath their costumes; these were intended as ridiculous and were meant to be laughed at. In Aristophanes's comedy The Clouds, "Mr. Good Reason" gives the character Pheidippides a description of the ideal youth: "A glistening chest and glowing skin / Broad shoulders, a small tongue /A mighty bottom and a tiny prong." In Greek mythology, Priapus, the god of fertility, had an impossibly large penis that was permanently erect. Priapus was widely seen as hideous and unattractive. A scholion on Apollonius of Rhodes's Argonautica states that when Priapus' mother Aphrodite, the goddess of love and beauty, gave birth to him, she was so horrified by the size of his penis, his massive potbelly, and his huge tongue that she abandoned him to die in the wilderness. A herdsman found him and raised him as his son, later discovering that Priapus could use his massive penis to aid in the growth of plants.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It acts as a dual agonist at the GIP receptor and the GLP-1 receptor. This broader targeting profile distinguishes it from selective GLP-1 agonists, which engage only one receptor.